Loading stock data…
LONZA N (LONN.SW)
CHF 539.60+5.00 (+0.94%)
Market OpenUpdated 11:31 AM EDT
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lonza Group AG in the Healthcare sector is trading at $539.60 with a market capitalization of $34.8B. Wall Street consensus targets $665.48 (23 analysts), implying a +23.3% move over the next 12 months. The stock is currently 9% below its 52-week high of $594.80, remaining 4.0% above its 200-day moving average. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (CHF) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | CHF 6.22B↓ | CHF 6.72B↑ | CHF 5.48B↓ | CHF 6.53B |
| Gross Profit | CHF 2.44B↑ | CHF 1.95B↑ | CHF 1.79B↓ | CHF 2.31B |
| Operating Income | CHF 1.36B↑ | CHF 873.00M↓ | CHF 879.00M↓ | CHF 1.36B |
| Net Income | CHF 1.22B↑ | CHF 654.00M↑ | CHF 636.00M↑ | -CHF 275.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
CHF 34.79B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
38.29
Beta
Defensive asset. Lower volatility than the S&P 500.
0.89
Div Yield
Strong income play. Yield provides a meaningful total return floor.
98.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.48%
Volume
Today's trading volume
184,605
Recent News
Lonza Says Big Pharma Might Delay Outsourcing Decisions Amid U.S. Investments
The investments are more likely to represent a shift in spending toward the U.S. than a fundamental change in sourcing strategies, the contract drug manufacturer said.
Is Lonza Group (SWX:LONN) Pricing Too High After Recent Share Price Swings?
Wondering whether Lonza Group at about CHF 508 per share still makes sense for your portfolio, or if better value is available elsewhere? The stock has been fairly volatile recently, with a 4.8% decline over the last week, an 8.7% gain over the last month, and returns of 5.1% lower year to date and 8.9% lower over the last year. Recent coverage has focused on how Lonza Group fits into the wider life sciences sector and what that might mean for investor sentiment. This news context helps...
45% earnings growth over 1 year has not materialized into gains for Lonza Group (VTX:LONN) shareholders over that period
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...
Lonza Group AG's (VTX:LONN) Intrinsic Value Is Potentially 26% Below Its Share Price
Key Insights Lonza Group's estimated fair value is CHF412 based on 2 Stage Free Cash Flow to Equity Lonza Group is...
Can Mixed Fundamentals Have A Negative Impact on Lonza Group AG (VTX:LONN) Current Share Price Momentum?
Most readers would already be aware that Lonza Group's (VTX:LONN) stock increased significantly by 8.8% over the past...